Else Nutrition Holdings Inc. (TSXV:BABY) (OTCPK:BABYF) is a food and nutrition company that focuses on researching, developing, manufacturing, marketing, selling, and/or licensing plant-based food and nutrition products. These products are targeted for the infant, toddler, children, and adult markets.
Rich first brought BABY to the attention of his community in October. Just days after that video, the stock rose an astounding 61%! Now, as 2020 quickly approaches, Rich returns with another bullish BABY profile.
“You need to put BABY on your watch list, you need to put it on your radar,” he says. “I think Else Nutrition is going to be a beast in 2020.”
The Plant-Based Food and Formula Boom
You most likely already know about the great success of Beyond Meat (NASDAQ:BYND). The alternate meat stock had the best IPO of 2019, primarily because it has the first-mover advantage delivering plant-based foods to hungry consumers.
But plant-based foods aren’t just replacing meat products like burgers, pork, and chicken. They’re also creating healthier and safer food for babies, children, and adults.
The worldwide industry for infant formula is expected to reach $90 billion in value by 2025. As more parents than ever before are looking for healthier options for their children, Else Nutrition’s breakthrough, 100% plant-based, non-soy infant formula could not come at a better time.
Else Nutrition’s First Mover Advantage
The formula is the first of its kind on the market. Made from almonds and buckwheat, Else Nutrition’s formula is free of GMOs, pesticides, hormones, antibiotics, gluten, and phytoestrogens. This makes it a healthier and more natural option for toddlers (12–36 months) than dairy-based baby formulas.
Right now, the vast majority of infant formulas are milk-based. This unfortunately ignores the fact that cow’s milk is the number one allergen for children aged five or younger. Milk allergies currently affect half of all food-allergic children in America who are less than one year old.
On top of that, nearly all alternatives to milk-based formulas are soy-based. Yet approximately 40% percent of children allergic to cow’s milk are also allergic to soy milk.
This means there are millions of children who can’t drink cow’s milk nor any of the alternatives, save for Else Nutrition’s 100% plant-based formula. This kind of exclusive market reach is unprecedented, especially in a market as important as children’s health and nutrition.
In addition to its strong product offering, Else Nutrition has very strong IP protection. This is an important part of its plan to capitalize on being the first mover in the plant-based infant formula space.
BABY’s formula has been granted patents in 20 countries, including the United States, Australia, Japan, Ukraine, Israel, Russia, South Africa, and New Zealand. The company also has a further 50+ patents pending.
Finally, Else Nutrition is already earning revenue in Israel from the sale of its vegan baby snacks and various accessories. These products generated $900,000 for the company last year and will be launched in the US next year.
(Boss) BABY’s Performance
This morning, BABY stock jumped 16%, from $0.37 to $0.43. As the company gets ever closer to launching its products on the American market, investors and analysts are sure to take note of this exciting stock.
“We’ve got, like, three months before this BABY explodes,” says Rich. “They are pre-revenue, but they’re not far from it. In my opinion they are going to at least $1.00 next year, once they start posting revenue.”
What do you think? Is BABY bound to take off? Let us know what you think.
Featured image: DepositPhotos © vitmarkov